BTIG Affirms 'Buy' Rating on Synergy Pharma (SGYP) Ahead of Pivotal Plecanatide Data in IBS-C
Tweet Send to a Friend
BTIG affirms Synergy Pharma (Nasdaq: SGYP) at Buy with a price target of $11 ahead of the potential release of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE